En undersøgelse for at se, om østrogen kan bremse væksten af nogle ER-positive brystkræft (PRESTO)
Præoperativ ESTradiOl Window of Opportunity-undersøgelse i postmenopausale kvinder med nyligt diagnosticeret ER positiv brystkræft
Some breast cancers have estrogen receptors (ER+). The investigators know that some ER+ tumours can be cured by hormone therapy alone while other ER+ breast cancers cannot. Currently, there is no perfect way to tell these groups apart nor do the investigators know why some respond when others do not.
Research findings suggest that the two types of ER+ breast cancers differ in their response to estrogen with estrogen being toxic to one type and not the other. For those tumours that find estrogen toxic, this may explain why tumours only start to grow when estrogen levels decrease after menopause.
The purpose of this study is to see whether a two-week treatment of estrogen equal to pre-menopausal estrogen levels will decrease the rate at which patients' ER+ tumours grow. This will be done by comparing the growth rate in the tissue removed during standard of care surgery after patients have been treated with 7-14 days of estrogen prior to that surgery.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Breast cancer is a heterogeneous disease that includes two ER+ genetic subtypes (luminal A and luminal B) that differ in their response to treatment.
Results from the Women's Health Initiative Trial showed that estrogen treated hysterectomized women with no prior history of breast cancer had a significant and persistent decrease in breast cancer incidence when compared to placebo treated participants. This implies that some ER+ breast cancers are in fact growth inhibited by estrogens and are not growth promoted.
The hypothesis of this study is that some ER+ breast cancers (luminal A) are actually sensitive (growth inhibited) by estrogen.
Objectives:
- To assess changes in breast cancer proliferation after a 7-14 day trial of estradiol in newly diagnosed estrogen receptor positive post-menopausal breast cancer patients prior to surgery.
- Exploratory analysis of biologic correlates with comparison to available genotyping tests.
This is an open-label single group assignment pilot study for safety/efficacy and exploratory biologic correlates
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Cross Cancer Institute
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Female gender
- Estrogen receptor positive (ER+) breast cancer
- HER2 negative breast cancer
- Post-menopausal by greater than 5 years
- No previous hormonal replacement therapy
- Low to intermediate histologic grade
- ECOG Performance status of 0 of 1
- Adequate hematological, renal and hepatic function is required
- Ability to take oral medication
- Patient must have adequate tissue for diagnosis, biomarkers and Ki67 assays
Exclusion Criteria:
- Pre-menopausal women
- Locally advanced or metastatic breast cancer
- Current, previous or planning for pre-operative treatment with chemotherapy, hormone therapy including corticosteroids, radiation therapy for malignancy or other condition
- Known hypersensitivity or intolerance to estradiol
- Ischemic changes on baseline electrocardiogram
- Symptomatic but untreated cholelithiasis
- History of deep vein thrombosis, pulmonary embolism, stroke, acute myocardial infarction, congestive cardiac failure, untreated hypertension or known inherited hypercoagulable disorder
- Undiagnosed abnormal vaginal bleeding or prior history of endometrial cancer
- Untreated metabolic disturbances (glucose > 15.0 mmol/L and triglycerides > 400 mg/dL)
- Current treatment with drugs known to be moderate or strong inhibitors of inducers of isoenzyme CYP3A4
- The time between study enrolment and definitive breast surgery is not sufficient for administration of at least 7 days of estradiol
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Estradiol treatment
Estradiol 6 mg daily for 7-14 days |
Eligible participants will take 2 mg Estradiol 3 times daily for 7-14 days pre-surgery.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
At vurdere ændringer i brystkræftproliferation efter et 7-14 dages forsøg med østradiol hos nydiagnosticerede østrogenreceptorpositive postmenopausale brystkræftpatienter før operation.
Tidsramme: afslutning på 7-14 dages behandling med østradiol
|
afslutning på 7-14 dages behandling med østradiol
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Eksplorativ analyse af biologiske korrelerer med sammenligning med tilgængelige genotypetests
Tidsramme: afslutning på 7-14 dages behandling med østradiol
|
afslutning på 7-14 dages behandling med østradiol
|
|
Analyse af data om tilbagefald/overlevelse baseret på initial Ki67-respons på 7-14 dages forsøg med østradiol.
Tidsramme: 10 år
|
10 år
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Judith Hugh, MD, University of Alberta
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Lægemidlers fysiologiske virkninger
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Farmakologiske handlinger
- Kemiske handlinger og anvendelser
- Polycykliske forbindelser
- Steroider
- SMUSED-RING-forbindelser
- Estrenes
- Estraner
- Estradiol kongenere
- Gonadale steroidhormoner
- Gonadale hormoner
- Østrogener
- Østradiol
Andre undersøgelses-id-numre
- EER001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .